Sign in
TerminatedPhase 1

Phase I Study of the BBP-398 in Patients With Advance Solid Tumors

Key facts

Who runs it
LianBio LLC
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 1
People taking part
7 people enrolled
Started
18 Oct 2022
Ended
29 Mar 2024
Type of study
Interventional
Treatments tested
  • BBP-398
Record updated
25 June 2024
Why it stopped
Business reason

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Patients must have the ability to understand and the willingness to sign a written informed consent document 2 Patients must be willing and able to comply with the scheduled visits, treatment plan, laboratory tests and other specified study procedures 3. Age ≥18, male or female 4.Dose escalation: locally advanced or metastatic solid tumors Dose expansion: Advanced or metastatic EGFR-mutant NSCLC 5. Patients must have measurable disease by RECIST v1.1. 6. Patients must have an ECOG performance status (PS) ≤2 7.Patients with a life expectancy of ≥12 weeks. 8. Patients must have adequate organ function

Who cannot take part

  • Patients who have previously received a SHP-2 inhibitor
  • Treatment with any of the related anti-cancer therapies prior to the first dose of BBP-398 within the stated timeframes
  • Patients with a history of CVA, myocardial infarction or unstable angina within the previous 6 months before starting therapy
  • Patients with persisting toxicity related to prior therapy
  • Patients who have undergone major surgery within 4 weeks prior to study enrollment
  • Patients with a known additional malignancy that is progressing or requires active treatment
  • Patients who are hypersensitivity to SHP-2 inhibitor or any ingredients
  • Patients with known active Hepatitis B, Hepatitis C infection, or HIV infection
  • Patients with any of the cardiac-related issues or findings
  • Patients with inability to swallow oral medications or with gastrointestinal illness that would preclude the absorption of an oral agent
  • Patients with known central nervous system (CNS) tumors
  • Patients with known active CNS metastases and/or carcinomatous meningitis
  • Pregnant or breastfeeding female patients

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is an open label, dose escalation and expansion, two-part Phase I study for SHP-2 inhibitor BBP-398 to evaluate the safety, tolerability, pharmacokinetics, determine MTD and/or RP2D, and preliminary anti- cancer activity in Chinese subjects with advanced solid tumors and in Chinese subjects with advanced or metastatic EGFR-mutant NSCLC.

The group in the trial

  • Part A Dose Escalation and Part B Dose ExpansionTreatment being tested

    Part A: Oral capsules taken in escalating levels to determine MTD/RP2D. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD). Part B: Oral capsules administered at MTD/RP2D defined dose. Each treatment cycle will be 28 days in duration with BBP-398 administered, once daily (QD)

    Treatment: BBP-398

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase I, Open Label, Dose Escalation and Expansion, Two- Part Study of SHP-2 Inhibitor BBP-398 to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-cancer Activity in Chinese Subjects With Advanced Solid Tumors
Record updated
25 June 2024